GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Consolidated Financial Statements for the year ended March 31, 2022 232 ( ` in lakhs ) Year ended March 31, 2022 Year ended March 31, 2021 Cost audit fees 5.70 5.92 Corporate social responsibility (Refer Note 38) 5,25.50 7,09.56 Commission to non whole-time Directors 95.00 1,43.06 Directors' sitting fees 47.50 49.00 Legal and professional fees 35,96.56 11,72.13 Miscellaneous 47,05.89 68,58.12 549,72.90 454,44.72 Note 37 : T he recurring expenditure on research and development charged off to statement of profit and loss amounts to ` 1,82.85 lakhs (Previous Year: ` 1,80.72 lakhs). Note 38 : Expenses towards CSR by the Parent Company Expense towards activities relating to Corporate Social Responsibility in compliance with section 135 of the Companies Act, 2013 is as under: ( ` in lakhs ) Year ended March 31, 2022 Year ended March 31, 2021 a) Amount required to be spent by the Parent Company during the year* 12,53.68 10,86.04 b) Amount of expenditure incurred (net of inter-company elimination) 5,88.18 7,63.86 c) Nature of CSR activities Partnering India to eliminate lymphatic filariasis (LF) ; GSK Scholars – Enabling future healthcare professionals; Healthy School Environment - The right of every child. Partnering India to eliminate lymphatic filariasis (LF) ; GSK Scholars – Enabling future healthcare professionals; Healthy School Environment - The right of every child. d) Details of related party transactions 6,65.55 3,23.43 e) Where the provision is made with respect to a liability incurred by entering into a contractual obligation , the movement in provision NA NA * The above includes allocation of ` 62.68 lakhs (Previous Year ` 54.30 lakhs) towards Corporate Social Responsibility which are shown under Employee Benefits Expenses in note 33. Note 39 : Exceptional Items ( ` in lakhs ) Year ended March 31, 2022 Year ended March 31, 2021 Profit on sale of property 31,40.01 1,84.09 Impairment of Assets (Refer Note (b) below) - (209,00.00) Associated cost to Impairment (Refer Note (c) below) 1,70.10 - Provision for product recall (Refer Note (a) below) - 34,80.26 Impairment of Nashik Assets (1,44.02) - Redundancy Costs (Refer Note (d) below) (20,08.43) (24.04) 11,57.66 (172,59.69) Notes: a) The Ultimate Holding Company had been contacted by regulatory authorities in 2019 regarding the detection of genotoxic nitrosamine NDMA in ranitidine products. Based on the information received and correspondence with regulatory authorities, the Ultimate Holding Company had made the decision to suspend the release, distribution and supply of all dose forms of ranitidine hydrochloride products to all markets, including India, as a precautionary action.